Qiagen confirmed it is assessing strategic options after media reports that the company has held preliminary talks with potential buyers, including U.S. strategics. Bloomberg and other outlets reported the board is working with advisers to evaluate interest, prompting a rebound in the stock to around $50 per share. J.P. Morgan analyst commentary noted the company has long been viewed as a takeout candidate. The review follows past acquisition interest—Thermo Fisher’s failed 2020 bid—and could reshape the life-science tools and diagnostics competitive landscape depending on any outcome. Qiagen declined to comment beyond routine disclosures; market participants are watching for staged disclosures or a potential sale process.